LoDoCo-TAVRNCT07411768
Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria shortened, about 13 words
- Start date changed from estimate of Mar 2026 to Mar 12, 2026
- Secondary endpoints: details revised at 2 of 3 entries
- Site details revised
- Notable Eligibility criteria expanded, about 127 words
- Study description expanded, about 51 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of Transcatheter Heart Valve (THV) Thrombosis
Timeframe: 1 year
Secondary (3)
Clinical Composite Endpoint: Including stroke, rehospitalization for heart failure, valve dysfunction, and all-cause mortality
Dynamic Changes in Inflammatory/Coagulation Biomarkers
Safety Evaluation: Incidence of adverse drug reactions and laboratory abnormalities
Arms and interventions
Colchicine GroupExperimental
0.5 mg once daily (QD) orally for 12 months, starting after successful TAVR and stabilization before discharge, on top of standard care.
Conventional TreatmentActive comparator
Standard pharmacological management and long-term postoperative care according to current clinical guidelines and expert consensus for TAVR patients, without the use of colchicine.
Drugs: Colchicine
Other: Standard Care
Sites
1 site in 1 country
- Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China